For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Tafamidis and Tafamidis meglumine represents a significant change. These novel therapies preserve the transthyretin protein, halting its damaging build-up and reducing the severity of